Autonomix Medical (AMIX) Proxy filing summary

Executive summary

• Annual Meeting scheduled for October 30, 2025, with both in-person and proxy voting options available.

• Shareholders of record as of September 8, 2025, are eligible to vote on five key proposals.

• Proxy materials are distributed electronically to reduce environmental impact and costs.

Voting matters and shareholder proposals

• Election of five directors to serve until the 2026 annual meeting.

• Ratification of Forvis Mazars, LLP as independent auditor for fiscal year ending March 31, 2026.

• Approval for a reverse stock split at a ratio between 1-for-2 and 1-for-25, at the Board's discretion, to maintain Nasdaq listing and improve trading liquidity.

• Amendment to the 2023 Equity Incentive Plan to increase authorized shares from 371,968 to 2,271,968.

• Approval to issue more than 20% of outstanding common stock under a purchase agreement with Lincoln Park Capital Fund, LLC, providing up to $15 million in potential capital.

Board of directors and corporate governance

• Board consists of five members, with a majority deemed independent under Nasdaq rules.

• Board committees include Audit, Compensation, and Nominating & Corporate Governance, each with independent directors.

• Board and committees held a total of 22 meetings in fiscal 2025, with high attendance.

• Policies in place for director nominations, stockholder communications, and anti-hedging.